Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Acorda Therapeutics (NQ: ACOR )

9.883 -0.337 (-3.30%)
Streaming Delayed Price Updated: 11:47 AM EDT, Jun 6, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Acorda Therapeutics

< Previous 1 2 3 4 5 6 Next >
Acorda Therapeutics Announces Completion of 1-for-20 Reverse Stock Split
From Acorda Therapeutics
Via Business Wire
Acorda Therapeutics to Conduct 1-for-20 Reverse Stock Split
From Acorda Therapeutics
Via Business Wire
Acorda Therapeutics CEO Ron Cohen, M.D., to Hold Virtual Company Presentation and Q&A
From Acorda Therapeutics
Via Business Wire
Week In Review: BlissBio Announces Potential $2 Billion Deal With Eisai For HER2 ADC
Bliss Biopharma may out-license global rights for its HER2 ADC to Eisai Pharma in a deal with a potential value of $2 billion. Also, Junshi Bio out-licensed regional rights for its anti-PD-1 mAb to Dr.... 
Via Talk Markets
Acorda Therapeutics Reports First Quarter 2023 Financial Results
From Acorda Therapeutics
Via Business Wire
3 Penny Stocks to Avoid as Interest Rates Rise in 2023
This article reveals the worst penny stocks to invest in for 2023, amid rising interest rates and a deteriorating macro environment. 
Via InvestorPlace
Acorda Therapeutics to Make June 2023 $6.2 Million Interest Payment on Secured Debt in Cash
From Acorda Therapeutics
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
We're starting off the day with the biggest pre-market stock movers traders will want to keep in mind while trading on Tuesday! 
Via InvestorPlace
Global Alzheimer’s Disease Diagnostics & Therapeutics Market Expected to Reach $9.6 Billion by 2027
Palm Beach, FL – May 9, 2023 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease (AD) is a progressive and neurodegenerative disorder that attacks the brain’s nerve cells or neurons, which... 
Via FinancialNewsMedia
Topics Intellectual Property
Exposures Intellectual Property
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Acorda Therapeutics and Chance Pharmaceuticals Announce Agreement to Commercialize INBRIJA® in China
From Acorda Therapeutics
Via Business Wire
Acorda First Quarter 2023 Update: Webcast/Conference Call Scheduled for May 11, 2023
From Acorda Therapeutics
Via Business Wire
Acorda Therapeutics to Present INBRIJA® Data at the American Academy of Neurology Annual Meeting
From Acorda Therapeutics
Via Business Wire
Acorda Launches INBRIJA® TV Commercial for Parkinson’s Awareness Month
From Acorda Therapeutics
Via Business Wire
Acorda Therapeutics CEO Ron Cohen, M.D., to Hold Virtual Company Presentation and Q&A
From Acorda Therapeutics
Via Business Wire
Acorda Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
From Acorda Therapeutics
Via Business Wire
ESTEVE Launches INBRIJA® in Spain
From Acorda Therapeutics
Via Business Wire
Acorda Fourth Quarter/Year End 2022 Update: Webcast/Conference Call Scheduled for March 9, 2023
From Acorda Therapeutics
Via Business Wire
Acorda Therapeutics Receives Nasdaq Extension to Meet Minimum Bid Price Requirement
From Acorda Therapeutics
Via Business Wire
Acorda Therapeutics to Present at Sequire Biotechnology Conference
From Acorda Therapeutics
Via Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Acorda Therapeutics Announces New Agreement with Catalent for Long-Term Global Supply of INBRIJA®
From Acorda Therapeutics
Via Business Wire
Acorda Therapeutics Announces Revised Long-Term Financial Guidance
From Acorda Therapeutics
Via Business Wire
Acorda Therapeutics Receives Nasdaq Listing Determination Letter and Plans to Request a Hearing
From Acorda Therapeutics
Via Business Wire
Acorda Therapeutics Makes December 2022 $6.2 Million Interest Payment on Secured Debt in Cash
From Acorda Therapeutics
Via Business Wire
Acorda Therapeutics Announces Passage of Reverse Stock Split Proposal at its Special Meeting of Stockholders
From Acorda Therapeutics
Via Business Wire
How Is The Market Feeling About Acorda Therapeutics?
Acorda Therapeutics's (NASDAQ:ACOR) short percent of float has risen 230.3% since its last report. The company recently reported that it has 792 thousand shares sold short, which is 3.27% of all... 
Via Benzinga
Why Huadi International Group Shares Dipped Around 91%; Here Are 79 Biggest Movers From Yesterday
Gainers 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.